Production of recombinant protein therapeutics in cultivated mammalian cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advances in cell engineering, process control, and media composition are credited with improving the volumetric yield of cell culture bioprocesses, making biopharmaceutical manufacturing more cost-effective and practical [8].”
From The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing (2022) · cites this paper as [8]
In the citing paper
“Chinese hamster ovary (CHO) cells are one of the main cell lines used in the production of recombinant therapeutics (Wurm, 2004; see Grillberger et al., 2009 for examples of proteins produced in CHO cells).”
From Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing (2010) · cites this paper as Wurm, 2004
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451 · cited 1×
“In 1973, Graham and van der Eb showed that exposing cells to nanoparticles of DNA and calcium phosphate makes possible DNA transfer into cultivated mammalian cell”
BackgroundEpigenetic Codes for Heterochromatin Formation and Silencing
Richards, E. J., & Elgin, S. C. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00644-x · Cited by 871
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
How introns influence and enhance eukaryotic gene expression
Le Hir, H., Nott, A., & Moore, M. J. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00052-5 · Cited by 734
Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., & Yarranton, G. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-169 · Cited by 462 · cited 1×
“At a concentration of 10–100 μM MSX, resistant clones can be identified in selected NS0 cell populations that have amplified the transgene complex containing the GS gene and the desired gene(s) of interes”
BackgroundGenetic and physical linkage of exogenous sequences in transformed cells
Perucho, M., Hanahan, D., & Wigler, M. (1980) · Cell · doi:10.1016/0092-8674(80)90178-6 · Cited by 455 · cited 1×
“Nuclear ligases assure the covalent joining of individual plasmid DNA molecule”
BackgroundExpression of recombinant plasmids in mammalian cells Is enhanced by sodium butyrate
Gorman, C. M., Howard, B. H., & Reeves, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.21.7631 · Cited by 367 · cited 1×
“Another way to inhibit silencing is to block deacetylation of histones using butyrat”
BackgroundSilencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9
Mutskov, V., & Felsenfeld, G. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600013 · Cited by 296
Kim, S. J., Kim, N. S., Ryu, C. J., Hong, H. J., & Lee, G. M. (1998) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19980405)58:1<73::aid-bit8>3.0.co;2-r · Cited by 220 · cited 1×
“Thus, it might be advantageous to omit selective drugs once promising clonal cell lines have been identifie”
BackgroundLarge-scale transient expression in mammalian cells for recombinant protein production
Wurm, F., & Bernard, A. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)80027-5 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Gorman, C.M., Howard, B.H. & Reeves, R. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11, 7631–7648 (1983). · DOI · Paper page
Cited by
Items 201–300 of 1,007
Mammalian cell factories for efficient and stable protein expression
Barnes, L. M., & Dickson, A. J. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.06.005 · Cited by 117
Yang, B., Liu, J., Jiang, Y., & Chen, F. (2016) · Biotechnology Journal · doi:10.1002/biot.201500617 · Cited by 92
“Established expression systems include bacteria [2], yeast [3], insect cell lines [4], mammalian cell lines [5], animals [6], and plants [7].”
BackgroundOptimizing capacity utilization by large scale 3000 L perfusion in seed train bioreactors
Pohlscheidt, M., Jacobs, M., Wolf, S., Thiele, J., Jockwer, A., Gabelsberger, J., Jenzsch, M., Tebbe, H., & Burg, J. (2013) · Biotechnology Progress · doi:10.1002/btpr.1672 · Cited by 94
Noh, S. M., Shin, S., & Lee, G. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-23720-9 · Cited by 108
RNA interference of sialidase improves glycoprotein sialic acid content consistency
Ngantung, F. A., Miller, P. G., Brushett, F. R., Tang, G. L., & Wang, D. I. C. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20997 · Cited by 97
“At the end of 2004, it was estimated that 60–70% of the biopharmaceuticals were produced by mammalian cells (Wurm, 2004).”
BackgroundZhang, L., Inniss, M. C., Han, S., Moffat, M., Jones, H., Zhang, B., Cox, W. L., Rance, J. R., & Young, R. J. (2015) · Biotechnology Progress · doi:10.1002/btpr.2175 · Cited by 97
Douris, V., Swevers, L., Labropoulou, V., Andronopoulou, E., Georgoussi, Z., & Iatrou, K. (2006) · Advances in virus research · doi:10.1016/s0065-3527(06)68004-4 · Cited by 108
Predicting cell-specific productivity from CHO gene expression
Clarke, C., Doolan, P., Barron, N., Meleady, P., O’Sullivan, F., Gammell, P., Melville, M. W., Leonard, M. W., & CLYNES, M. M. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.11.016 · Cited by 114
“Cell and process engineering approaches to improve producivity in bioreactors have largely focussed on reactor design and ulture strategies such as clonal selection, stability, medium forulation, culture temperature and cell engineering for controlled roliferation and increased resistance to apoptosis (Altamirano t al…”
BackgroundLiu, C., Dalby, B., Chen, W., Kilzer, J. M., & Chiou, H. C. (2008) · Molecular Biotechnology · doi:10.1007/s12033-008-9051-x · Cited by 110
“Although the ultimate method for large-scale r-protein production in mammalian cells is to establish clones that stably express the gene of interest, this approach can be laborious, expensive, and time-consuming [9, 10 ].”
MethodHübbers, J., & Buyel, J. F. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107681 · Cited by 102
Cain, K., Peters, S., Hailu, H., Sweeney, B., Stephens, P., Heads, J., Sarkar, K., Ventom, A., Page, C., & Dickson, A. (2013) · Biotechnology Progress · doi:10.1002/btpr.1693 · Cited by 96
Dramatic performance improvement of weak anion-exchange membranes for chromatographic bioseparations
Bhut, B. V., & Husson, S. M. (2009) · Journal of Membrane Science · doi:10.1016/j.memsci.2009.03.046 · Cited by 94
Properties and Characterization of High Capacity Resins for Biochromatography
Müller, E. (2005) · Chemical Engineering & Technology · doi:10.1002/ceat.200500161 · Cited by 94
CHO microRNA engineering is growing up: Recent successes and future challenges
Jadhav, V., Hackl, M., Druz, A., Shridhar, S., Chung, C.-Y., Heffner, K. M., Kreil, D. P., Betenbaugh, M., Shiloach, J., Barron, N., et al. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.07.007 · Cited by 85
van Berkel, P. H. C., Gerritsen, J., Perdok, G., Valbjørn, J., Vink, T., van de Winkel, J. G. J., & Parren, P. W. H. I. (2009) · Biotechnology Progress · doi:10.1002/btpr.92 · Cited by 92
“Jefferis R. Glycosylation of human IgG.”
InfluentialKaufman, W. L., Kocman, I., Agrawal, V., Rahn, H.-P., Besser, D., & Gossen, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn508 · Cited by 108
“It will be interesting to further evaluate cell sorting as the basic principle for generating cell lines as an additional parameter in optimizing recombinant protein production ( 43 ).”
BackgroundXu, J., Xu, X., Huang, C., Angelo, J., Oliveira, C. L., Xu, M., Xu, X., Temel, D., Ding, J., Ghose, S., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1770669 · Cited by 89
Dynamic mRNA and miRNA profiling of CHO‐K1 suspension cell cultures
Bort, J. A. H., Hackl, M., Höflmayer, H., Jadhav, V., Harreither, E., Kumar, N., Ernst, W., Grillari, J., & Borth, N. (2012) · Biotechnology Journal · doi:10.1002/biot.201100143 · Cited by 86
Clarke, C., Henry, M. A., Doolan, P., Kelly, S., Aherne, S. T., Sanchez, N., Kelly, P. S., Kinsella, P., Breen, L., Madden, S. F., et al. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-656 · Cited by 110
“vectors and the design of bioreactors [20].”
Metze, S., Ruhl, S., Greller, G., Grimm, C., & Scholz, J. (2020) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-019-02216-4 · Cited by 79
Production systems for recombinant antibodies
Schirrmann, T., Al-Halabi, L., Dübel, S., & Hust, M. (2008) · Frontiers in bioscience · doi:10.2741/3024 · Cited by 115
The need for innovation in biomanufacturing
Gottschalk, U., Brorson, K., & Shukla, A. A. (2012) · Nature Biotechnology · doi:10.1038/nbt.2263 · Cited by 91
Tactic, reactive, and functional droplets outside of equilibrium
Lach, S., Yoon, S. M., & Grzybowski, B. A. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00242k · Cited by 95
Berting, A., Farcet, M. R., & Kreil, T. R. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22723 · Cited by 88
“Chinese hamster ovary (CHO) cells are one of the main cell lines used in the production of recombinant therapeutics (Wurm, 2004; see Grillberger et al., 2009 for examples of proteins produced in CHO cells).”
BackgroundInfluentialSystematic Transfer of Prokaryotic Sensors and Circuits to Mammalian Cells
Stanton, B. C., Siciliano, V., Ghodasara, A., Wróblewska, L., Clancy, K., Trefzer, A. C., Chesnut, J. D., Weiss, R., & Voigt, C. A. (2014) · ACS Synthetic Biology · doi:10.1021/sb5002856 · Cited by 92
Jedrzejczak-Silicka, M. (2017) · New Insights into Cell Culture Technology · doi:10.5772/66905 · Cited by 87
Klatt, S., Simpson, L., Maslov, D. A., & Konthur, Z. (2019) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007424 · Cited by 87
Differential protein expression following low temperature culture of suspension CHO-K1 cells
Kumar, N., Gammell, P., Meleady, P., Henry, M., & Clynes, M. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-42 · Cited by 79
“Background Since the introduction of human tissue plasminogen activator (tPA) as the first recombinant therapeutic protein product from mammalian cells to get approval in 1986, approximately 60–70% of all recombinant proteins are being produced in mammalian cell lines [1], predominantly in Chinese Hamster Ovary (CHO)…”
BackgroundProduction of target‐specific recombinant human polyclonal antibodies in mammalian cells
Wiberg, F. C., Rasmussen, S. K., Frandsen, T. P., Rasmussen, L. K., Tengbjerg, K., Coljee, V. W., Sharon, J., Yang, C., Bregenholt, S., Nielsen, L. S., et al. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20865 · Cited by 87
“Methods for development, manufacture, and regulatory approval of recombinant mAb are well established (Chadd and Chamow, 2001; Kipriyanov and Le Gall, 2004; Wurm, 2004).”
BackgroundBECKER, E., FLORIN, L., PFIZENMAIER, K., & KAUFMANN, H. (2008) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2008.03.008 · Cited by 86
“The most common industrial mammalian host cell systems for the production of biopharmaceuticals are immortalized Chinese hamster ovary (CHO) cell lines (Wurm, 2004).”
BackgroundPerez-Almodovar, E. X., & Carta, G. (2009) · Journal of Chromatography A · doi:10.1016/j.chroma.2009.09.017 · Cited by 86
Harnessing the potential of machine learning for advancing “Quality by Design” in biomanufacturing
Walsh, I., Myint, M., Nguyen-Khuong, T., Ho, Y. S., Ng, S. K., & Lakshmanan, M. (2022) · mAbs · doi:10.1080/19420862.2021.2013593 · Cited by 81
“Unlike small molecules, biopharmaceuticals are large, complex drugs that are typically produced using live mammalian cells.(2) The biological activity of biopharmaceuticals is extremely sensitive to variations in their critical quality attributes (CQAs), such as the N-glycosylation, charge distribution and aggregation.”
BackgroundBiopharmaceutical Manufacturing: Historical Perspectives and Future Directions
Szkodny, A. C., & Lee, K. H. (2022) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-092220-125832 · Cited by 105
Systems biotechnology of mammalian cell factories
O’Callaghan, P. M., & James, D. C. (2008) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/eln012 · Cited by 98
“In recent years increased productivity has largely been a consequence of the systematic optimization of media formulation and rational design of feeding regimes which primarily facilitate increased accumulation of cellular biomass in vitro and to a much lesser extent cell-specific production rate [5].”
Doolan, P., Meleady, P., Barron, N., Henry, M., Gallagher, R., Gammell, P., Melville, M., Sinacore, M., McCarthy, K., Leonard, M., et al. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22670 · Cited by 84
T cell engagers: expanding horizons in oncology and beyond
Albayrak, G., Wan, P. K.-T., Fisher, K. D., & Seymour, L. W. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03125-y · Cited by 95
“Most clinical TCEs today are produced in mammalian cell systems (primarily Chinese hamster ovary, CHO, cells) because these systems provide correct protein folding, assembly, and post-translational modi fi cations [61, 62].”
Alternative Affinity Ligands for Immunoglobulins
Kruljec, N., & Bratkovič, T. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00335 · Cited by 92
The emerging role of systems biology for engineering protein production in CHO cells
Kuo, C., Chiang, A. W. T., Shamie, I., Samoudi, M., Gutierrez, J. M., & Lewis, N. E. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.11.015 · Cited by 95
“, monoclonal antibodies) by three orders of magnitude, from 10-50mg/L in the 1980s to >10g/L in the 2010s [6,7].”
BackgroundStable microRNA expression enhances therapeutic antibody productivity of Chinese hamster ovary cells
Strotbek, M., Florin, L., Koenitzer, J. D., Tolstrup, A. B., Kaufmann, H., Haußer, A., & Olayioye, M. A. (2013) · Metabolic Engineering · doi:10.1016/j.ymben.2013.10.005 · Cited by 95
“These cells can easily be adapted to growth in suspension under serum-free conditions and engineered to stably secrete recombinant proteins of interest that are correctly processed and post-translationally modified (Jayapal et al., 2007; Wurm, 2004).”
BackgroundElectron Capture Dissociation Mass Spectrometry in Characterization of Peptides and Proteins
Bakhtiar, R., & Guan, Z. (2006) · Biotechnology Letters · doi:10.1007/s10529-006-9065-z · Cited by 94
“Moreover, proteins produced using bacterial and yeast expression systems, as well as insect and mammalian cell culture, are subjected to rigorous quality control scrutiny (Fuchs 2002; Janis and Davis 1994; Jones et al. 2005; Murano 1997; Roy and Gupta 2004; Wurn 2004).”
Lohse, S., Meyer, S., Meulenbroek, L. A. P. M., Jansen, J. H. M., Nederend, M., Kretschmer, A., Klausz, K., Möginger, U., Derer, S., Rösner, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1232 · Cited by 84
“In contrast to IgG1, IgA antibodies carry a more exposed and heterogeneous N-glycosylation (14-29): there are two conserved N-glycans in both IgA isotypes with two and three additional N-glycans for IgA2m(1) and IgA2m(2), respectively.”
BackgroundInfluentialGupta, S. K., & Shukla, P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00419 · Cited by 94
“Due to the employment of innovative technologies starting from cell line engineering to USP development approaches allows an enhanced mAb production from 50 mg/L (in 1986) to 5–20 g/L today (Wurm, 2004; Kelley, 2009; Chon and Zarbis-Papastoitsis, 2011).”
BackgroundSite-specific integration ushers in a new era of precise CHO cell line engineering
Hamaker, N. K., & Lee, K. H. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2018.09.011 · Cited by 88
“subpopulations present within the host cell culture before transfection as well as the differences in rDNA insertion sites among cells [6,7].”
BackgroundFermentanomics: Monitoring Mammalian Cell Cultures with NMR Spectroscopy
Bradley, S. A., Ouyang, A., Purdie, J., Smitka, T. A., Wang, T., & Kaerner, A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja101962c · Cited by 80
Process intensification in fed-batch production bioreactors using non-perfusion seed cultures
Yongky, A., Xu, J., Tian, J., Oliveira, C. L., Zhao, J. C., McFarland, K. S., Borys, M., & Li, Z. J. (2019) · mAbs · doi:10.1080/19420862.2019.1652075 · Cited by 84
Yu, M., Hu, Z., Pacis, E., Vijayasankaran, N., Shen, A., & Li, F. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23031 · Cited by 80
Xu, J., Rehmann, M. S., Xu, M., Zheng, S., Hill, C., He, Q., Borys, M., & Li, Z. J. (2020) · Bioresources and Bioprocessing · doi:10.1186/s40643-020-00304-y · Cited by 89
“2010; Rader and Langer 2015; Wurm 2004).”
Applications and analysis of hydrolysates in animal cell culture
Ho, Y. Y., Lu, H., Lim, Z. F. S., Lim, H. W., Ho, Y. S., & Ng, S. K. (2021) · Bioresources and Bioprocessing · doi:10.1186/s40643-021-00443-w · Cited by 84
“Although HEK293 became an immortalized cell line after being transformed with sheared adenovirus-5 DNA (Kovesdi and Hedley 2010), CHO cells were immortalized spontaneously (Wurm and Wurm 2017).”
BackgroundRivard, D., Anguenot, R., Brunelle, F., Le, V. Q., Vezina, L. P., Trépanier, S., & Michaud, D. (2006) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2006.00187.x · Cited by 89
Zhang, X., Stettler, M., Sanctis, D. D., Perrone, M., Parolini, N., Discacciati, M., Jesus, M., Hacker, D. L., Quarteroni, A. M., & Wurm, F. M. (2009) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2008_18 · Cited by 78
Self-citationSubedi, G. P., Johnson, R. W., Moniz, H. A., Moremen, K. W., & Barb, A. W. (2015) · Journal of Visualized Experiments · doi:10.3791/53568 · Cited by 89
Chalmers, J. J. (2015) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2015.09.005 · Cited by 79
MicroRNAs as targets for engineering of CHO cell factories
Müller, D., Katinger, H. W. D., & Grillari, J. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.03.010 · Cited by 94
Stock, J., Sarkari, P., Kreibich, S., Brefort, T., Feldbrügge, M., & Schipper, K. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.03.004 · Cited by 81
Hacker, D. L., Kiseljak, D., Rajendra, Y., Thurnheer, S., Baldi, L., & Wurm, F. M. (2013) · Protein Expression and Purification · doi:10.1016/j.pep.2013.09.001 · Cited by 83
“These cells were used as the host for the TGE method described here because they are efficiently transfected, grow to a high density in suspension culture, and are widely used in the biopharmaceutical industry to generate stable cell lines for the production of therapeutic proteins [1].”
Self-citationCMV promoter mutants with a reduced propensity to productivity loss in CHO cells
Moritz, B., Becker, P. B., & Göpfert, U. (2015) · Scientific Reports · doi:10.1038/srep16952 · Cited by 74
Hempel, F., Maurer, M. J., Brockmann, B., Mayer, C., Biedenkopf, N., Kelterbaum, A., Becker, S., & Maier, U. G. (2017) · Microbial Cell Factories · doi:10.1186/s12934-017-0745-2 · Cited by 80
“Chinese hamster ovary (CHO) cells [2, 3].”
Virus‐Like Particle Engineering: From Rational Design to Versatile Applications
Ding, X., Liu, D., Booth, G., Gao, W., & Lu, Y. (2018) · Biotechnology Journal · doi:10.1002/biot.201700324 · Cited by 82
A review on edible vaccines and their prospects
Bharath, G., & Muthukaliannan, G. K. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198749 · Cited by 76
“Vaccines are generally produced by industrial processes, thus making them expensive and inaccessible in developing countries (2,3).”
BackgroundModern Technologies for Creating Synthetic Antibodies for Clinical Application
Deyev, S. M., & Lebedenko, E. N. (2009) · Acta Naturae · doi:10.32607/20758251-2009-1-1-32-50 · Cited by 86
Challenges to production of antibodies in bacteria and yeast
Lee, Y. J., & Jeong, K. J. (2015) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2015.03.009 · Cited by 86
Surface wave dynamics in orbital shaken cylindrical containers
Reclari, M., Dreyer, M., Tissot, S., Obreschkow, D., Wurm, F. M., & Farhat, M. (2014) · Physics of Fluids · doi:10.1063/1.4874612 · Cited by 76
Self-citationHo, S. C. L., Bardor, M., Li, B., Lee, J. J., Song, Z., Tong, Y. W., Goh, L., & Yang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063247 · Cited by 80
“vectors [3–6].”
Orellana, C. A., Marcellin, E., Schulz, B. L., Nouwens, A. S., Gray, P. P., & Nielsen, L. K. (2015) · Journal of Proteome Research · doi:10.1021/pr501027c · Cited by 75
Amribt, Z., Niu, H., & Bogaerts, P. (2012) · Biochemical Engineering Journal · doi:10.1016/j.bej.2012.11.005 · Cited by 76
Tamura, A., Kobayashi, J., Yamato, M., & Okano, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.060 · Cited by 76
“vaccines and antibodies), this culture method has already been employed for expanding a large number of cells [11,12].”
MethodTailoring recombinant protein quality by rational media design
Brühlmann, D., Jordan, M., Hemberger, J., Sauer, M., Stettler, M., & Broly, H. (2015) · Biotechnology Progress · doi:10.1002/btpr.2089 · Cited by 71
Clarke, C., Doolan, P., Barron, N., Meleady, P., O’Sullivan, F., Gammell, P., Melville, M. W., Leonard, M. W., & CLYNES, M. M. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.07.011 · Cited by 98
BioPreDyn-bench: a suite of benchmark problems for dynamic modelling in systems biology
Villaverde, A. F., Henriques, D., Smallbone, K., Bongard, S., Schmid, J., Cicin-Sain, D., Crombach, A., Sáez-Rodríguez, J., Mauch, K., Balsa‐Canto, E., et al. (2015) · BMC Systems Biology · doi:10.1186/s12918-015-0144-4 · Cited by 88
“(CHO) cells Chinese Hamster Ovary cells (CHO) are used for protein production in fermentation processes [60].”
Peng, R., & Fussenegger, M. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22141 · Cited by 70
Genomics and proteomics in process development: opportunities and challenges
Gupta, P., & Lee, K. H. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.04.005 · Cited by 90
Liquid Chromatography—Its Development and Key Role in Life Science Applications
Unger, K. K., Ditz, R., Machtejevas, E., & Skudas, R. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200906976 · Cited by 74
Monoclonal antibody disulfide reduction during manufacturing
Hutterer, K. M., Hong, R. W., Lull, J., Zhao, X., Wang, T., Pei, R., Le, M. E., Borisov, O., Piper, R., Liu, D., et al. (2013) · mAbs · doi:10.4161/mabs.24725 · Cited by 74
“Both copy number and insertion site can vary from clone to clone, and both of these parameters may also affect cell growth, viability, productivity, and metabolism.(12,13) Therefore, to partially disentangle the effect of product, cell line and process on the level of reduction, end of production cells from these thre…”
BackgroundMüller, N., Derouazi, M., Tilborgh, F. V., Wulhfard, S., Hacker, D. L., Jordan, M., & Wurm, F. M. (2007) · Biotechnology Letters · doi:10.1007/s10529-006-9298-x · Cited by 74
“may yield as much as 4 g antibody/l with specific productivities of 50 pg/cell d or more (Wurm 2004).”
BackgroundSelf-citationBalasubramanian, S., Rajendra, Y., Baldi, L., Hacker, D. L., & Wurm, F. M. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25888 · Cited by 75
Self-citationMajors, B. S., Betenbaugh, M. J., Pederson, N. E., & Chiang, G. G. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21917 · Cited by 69
Smejkal, B. M., Agrawal, N. J., Helk, B., Schulz, H., Giffard, M., Mechelke, M., Ortner, F., Heckmeier, P. J., Trout, B. L., & Hekmat, D. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24908 · Cited by 73
Hansen, H. G., Pristovšek, N., Kildegaard, H. F., & Lee, G. M. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.11.008 · Cited by 84
“SGE is a prerequisite for the stable, large-scale manufacturing of r-proteins as biologics for clinical applications (Noh et al., 2013; Wurm, 2004).”
BackgroundInfluentialMammalian cell cultivation using nutrients extracted from microalgae
Okamoto, Y., Haraguchi, Y., Sawamura, N., Asahi, T., & Shimizu, T. (2019) · Biotechnology Progress · doi:10.1002/btpr.2941 · Cited by 75
“For the treatment/prevention of various diseases, biopharmaceuticals and vaccines produced by cultured mammalian cells are used.(5) Cultured cells have also greatly contributed to the advancement of basic academic science fields such as cell biology, biochemistry, genetics, physiology, and molecular biology.”
BackgroundControl of Erythropoietin Gene Expression and its Use in Medicine
JELKMANN, W. E. B. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35010-6 · Cited by 82
Oberbek, A., Matasci, M., Hacker, D. L., & Wurm, F. M. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22968 · Cited by 75
“Recombinant proteins produced from stable mammalian cell lines are of interest to fundamental and clinical researchers as well as to the biopharmaceutical industry (Wurm, 2004).”
BackgroundMethodSelf-citationCell-Free Synthesis Meets Antibody Production: A Review
Stech, M., & Kubick, S. (2015) · Antibodies · doi:10.3390/antib4010012 · Cited by 83
“specifications—and finally up-scaling, process characterization and validation [39–41].”
BackgroundIn-situ imaging sensors for bioprocess monitoring: state of the art
Bluma, A., Höpfner, T., Lindner, P., Rehbock, C., Beutel, S., Riechers, D., Hitzmann, B., & Scheper, T. H. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4181-y · Cited by 72
Metabolic engineering of CHO cells to alter lactate metabolism during fed-batch cultures
Toussaint, C., Henry, O., & Durocher, Y. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.11.010 · Cited by 66
“The development and implementation of high-yield fed-batch strategies has contributed greatly at increasing the productivity of mammalian cell cultures (Bibila and Robinson, 1995; Wlaschin and Hu, 2006; Wurm, 2004).”
BackgroundTorkashvand, F., Vaziri, B., Maleknia, S., Heydari, A., Vossoughi, M., Davami, F., & Mahboudi, F. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140597 · Cited by 70
“Manufacturers spend extensive efforts and time on the optimization of culture media and feeds as a basic development process for each cell line [4, 6].”
BackgroundMethods for Generating Hydrogel Particles for Protein Delivery
Liu, A. L., & García, A. J. (2016) · Annals of Biomedical Engineering · doi:10.1007/s10439-016-1637-z · Cited by 77
Thoring, L., Wüstenhagen, D. A., Borowiak, M., Stech, M., Sonnabend, A., & Kubick, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163670 · Cited by 77
Advances in Membrane Technologies
Abdelrasoul, A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.82587 · Cited by 81
Advancing mammalian cell culture engineering using genome-scale technologies
Griffin, T. J., Seth, G., Xie, H., Bandhakavi, S., & Hu, W. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.07.004 · Cited by 85
A multi-Fc-species system for recombinant antibody production
Moutel, S., Marjou, A. E., Vielemeyer, O., Nizak, C., Benaroch, P., Dübel, S., & Perez, F. (2009) · BMC Biotechnology · doi:10.1186/1472-6750-9-14 · Cited by 71
“It is likely however that higher production may be achievable after optimization [see [16]].”
Porter, A. J., Racher, A. J., Preziosi, R., & Dickson, A. J. (2010) · Biotechnology Progress · doi:10.1002/btpr.443 · Cited by 71
Sleiman, R. J., Gray, P. P., McCall, M. N., Codamo, J., & Sunstrom, N. S. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21612 · Cited by 70
“Mammalian cell lines such as Chinese hamster ovary (CHO) offer distinct advantages (reviewed in Wurm, 2004), including the ability to grow to high cell densities in serum-free media (Sinacore et al., 2000).”
BackgroundGüler-Gane, G., Kidd, S., Sridharan, S., Vaughan, T. J., Wilkinson, T. C. I., & Tigue, N. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155340 · Cited by 80
“The observation that tyrosine, cysteine and proline were not favoured at the +1 position correlates with a lower prevalence of these amino acids in the +1 position of endogenous proteins [1,2,18], which could reflect a natural mechanism to regulate the expression and secretion of such proteins to an appropriate physio…”
BackgroundMethodRecent advances in mRNA vaccine delivery
Tan, L., & Sun, X. (2018) · Nano Research · doi:10.1007/s12274-018-2091-z · Cited by 78
“A new modified dendrimerRNA nanoparticle vaccine system can be developed in approximately 1 week [122], while traditional vaccines based on cell cultures or fertilized eggs can require at least 6 months [123, 124].”
BackgroundSelection of chemically defined media for CHO cell fed-batch culture processes
Pan, X., Streefland, M., Dalm, C., Wijffels, R. H., & Martens, D. E. (2017) · Cytotechnology · doi:10.1007/s10616-016-0036-5 · Cited by 70
“Chinese Hamster Ovary (CHO) cells are the main production host for recombinant therapeutic proteins (Wurm 2004).”
BackgroundIn pursuit of a super producer—alternative paths to high producing recombinant mammalian cells
Seth, G., Charaniya, S., Wlaschin, K. F., & Hu, W. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.012 · Cited by 81
Wen, D., Vecchi, M. M., Gu, S., Su, L., Dolníková, J., Huang, Y., Foley, S. F., Garber, E. A., Pederson, N. E., & Meier, W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.059360 · Cited by 70
Zhang, X., Bürki, C., Stettler, M., Sanctis, D. D., Perrone, M., Discacciati, M., Parolini, N., Dejesus, M., Hacker, D., Quarteroni, A., et al. (2009) · Biochemical Engineering Journal · doi:10.1016/j.bej.2009.02.003 · Cited by 76
Self-citationAdvances in antibody engineering for rheumatic diseases
Schmid, A. S., & Neri, D. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0188-8 · Cited by 72
Metabolic Flux Analysis in Systems Biology of Mammalian Cells
Niklas, J., & Heinzle, E. (2011) · Springer eBooks · doi:10.1007/10_2011_99 · Cited by 79
Metadata
- Authors
- Wurm, F. M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Wurm, Florian M
- ORCID
- Wurm, Florian M
- Venue
- Nature Biotechnology
- Published
- 2004-11
- Volume
- 22
- Issue
- 11
- Pages
- 1393-1398
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2118540273
- Cited by
- 2,032
- References
- 52
- Citations by year
- 2026: 52 · 2025: 51 · 2024: 66 · 2023: 66 · 2022: 64 · 2021: 77 · 2020: 89 · 2019: 114 · 2018: 162 · 2017: 118 · 2016: 95 · 2015: 135 · 2014: 108 · 2013: 145 · 2012: 111
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- recombinant therapeutic proteins, mammalian cell culture, bioreactors, protein folding, post-translational modification, volumetric productivity, culture medium optimization, process control, vector engineering, host cell engineering
- MeSH terms
- Animals, Cells, Cultured, Humans, Mammals, Recombinant Proteins, Transfection, Protein Engineering, Cell Culture Techniques, Bioreactors, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.